PE-22-28

PE-22-28 (also known as Spadin analog, TREK-1 blocker) is a prominently researched experimental compound classified strictly within the Nootropic Peptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it synthetic hexapeptide fragment derived from the propeptide of sortilin, an endogenous regulator of the TREK-1 potassium channel. PE-22-28 competitively inhibits TREK-1, a background leak channel whose overactivation is implicated in depression and anxiety. By blocking TREK-1, PE-22-28 increases neuronal excitability in serotonergic circuits and promotes BDNF expression, producing rapid antidepressant effects in rodent models comparable to fluoxetine. with a documented biological half-life of roughly 1 hours, In preclinical investigative trials and independent academic studies, researchers utilizing PE-22-28 have documented significant, quantifiable biological outcomes, primarily focusing on antidepressant, neuroplasticity, trek-1 channel blockade, fast-acting mood elevation. Typical research protocols investigate administering 500 to 1000mcg via subq pathways daily. However, it is critically important to understand that while PE-22-28 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.